康希諾(06185.HK)吸入式新冠疫苗擬已開啟三期試驗 可申請內地緊急使用
據《澎湃新聞》引述全國政協委員、康希諾生物(06185.HK)(688185.SH)首席科學官朱濤透露,康希諾生物的吸入式新冠疫苗在去年完成一、二期的臨床,啟動萬人左右的臨床試驗來做大規模的安全性和免疫原性的橋接。
朱濤透露,已開啟吸入用新冠疫苗三期臨床試驗,三期試驗有兩個類型,一個類型主要是考察大規模的安全性和免疫原性,是通過免疫原性、抗體水平的橋接來支持註冊的;另一個類型的三期是考察其大規模的安全性和保護效力。如果有效力結果,按照內地管理方法,可申請緊急使用。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.